Scroll
To Top

Archives for: July 30th, 2015

NORD Issues Statement on FDA’s New Associate Director for Rare Diseases

Written by Jennifer Huron on July 23, 2015

The following statement was issued by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), on today’s announcement that Jonathan C. Goldsmith, MD, FACP, will lead the Rare Diseases Program in the Center for Drug Evaluation and Research (CDER) Office of New Drugs at the… Read More

NORD Issues Statement on House’s Approval of 21st Century Cures Initiative

Written by Jennifer Huron on July 10, 2015

Washington, D.C. – July 10, 2015 – The following statement was issued by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), on today’s approval by the House of the 21st Century Cures legislative initiative.

Today’s passage in the House of the 21st Century Cures (H.R…. Read More

Impact of the Orphan Drug Tax Credit on Treatments for Rare Diseases

Written by Jennifer Huron on June 17, 2015

 

Today, the National Organization for Rare Disorders (NORD), Biotechnology Industry Organization (BIO), and Ernst & Young released “Impact of the Orphan Drug Tax Credit on Treatments for Rare Diseases,” a new white paper examining the role of the Orphan Drug Tax Credit (ODTC) on rare disease drug discovery.   Patients share… Read More